Prostate Cell News Volume 5.28 | Aug 1 2014

    0
    31
    Prostate Cell News 5.28 August 1, 2014

    Prostate Cell News

         In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
    Cell Therapy News on Facebook  PCN on Twitter

     
    TOP STORY
    The Role of PI3K/AKT-Related PIP5K1α and the Discovery of Its Selective Inhibitor for Treatment of Advanced Prostate Cancer
    Scientists report that overexpression of phosphatidylinositol-4-phosphate 5-kinase-α (PIP5K1α) in PNT1A nonmalignant cells resulted in an increased AKT activity and an increased survival, as well as invasive malignant phenotype, whereas siRNA-mediated knockdown of PIP5K1α in aggressive PC-3 cells led to a reduced AKT activity and an inhibition in tumor growth in xenograft mice. [Proc Natl Acad Sci USA] Abstract
    [Free On-Demand Webinar] Potential Applications of ALDH+ Cells in Regenerative Medicine - Watch Now.

     
    PUBLICATIONS (Ranked by impact factor of the journal)
    LABORATORY RESEARCH

    Genetic Ablation of Metadherin Inhibits Autochthonous Prostate Cancer Progression and Metastasis
    Researchers demonstrate that direct silencing of metadherin (MTDH) in prostate cancer cells decreased proliferation in vitro and tumor growth in vivo, supporting an epithelial cell-intrinsic role of MTDH in prostate cancer. [Cancer Res] Abstract

    Androgen-Regulated microRNA-135a Decreases Prostate Cancer Cell Migration and Invasion Through Downregulating ROCK1 and ROCK2
    Using xenograft experiments in chick embryos and adult male mice, researchers showed that miR-135a overexpression decreased in vivo invasion abilities of prostate PC-3 cells. [Oncogene] Abstract

    Ion Channel TRPM8 Promotes Hypoxic Growth of Prostate Cancer Cells via an O2-Independent and RACK1-Mediated Mechanism of HIF-1α Stabilization
    Scientists identified a mechanistic insight on how TRPM8 promotes the hypoxic growth adaptation of cancer cells via its promotion of RACK1-mediated stabilization of HIF-1α and a potential therapeutic strategy for prostate cancer by targeting TRPM8. [J Pathol] Abstract

    Castration-Induced Bone Loss Triggers Growth of Disseminated Prostate Cancer Cells in Bone
    Researchers used an in vivo model mimicking androgen ablation to establish the effects of this intervention on disseminated prostate cancer cells in bone. [Endocr Relat Cancer] Abstract

    Prostate Cancer Cell Malignancy via Modulation of HIF-1α Pathway with Isoflurane and Propofol Alone and in Combination
    The prostate cancer cell line PC3 was exposed to commonly used anesthetic isoflurane and propofol. Malignant potential was assessed through evaluation of expression level of hypoxia-inducible factor-1α (HIF-1α) and its downstream effectors, cell proliferation and migration as well as development of chemoresistance. [Br J Cancer] Abstract

    Altered Endosome Biogenesis in Prostate Cancer has Biomarker Potential
    A panel of endosomal markers was evaluated by investigators in prostate cancer and non-malignant cells and a significant increase in gene and protein expression was found for early, but not late endosomal proteins.
    [Mol Cancer Res]
    Abstract

    Inhibition of Hsp90 Augments Docetaxel Therapy in Castrate Resistant Prostate Cancer
    Scientists report that a second generation heat shock protein 90 (Hsp90) inhibitor, NVP-AUY922, inhibited cell growth and significantly induced cell death in MYC-CaP/CR and Pten-CaP/cE2 cell lines. [PLoS One]
    Full Article

    Effect of Lycopene Isolated from Chlorella marina on Proliferation and Apoptosis in Human Prostate Cancer Cell Line PC-3
    Scientists assessed the anti-proliferative and apoptotic effect of lycopene from a new source and compared the activity with available trans-lycopene by using androgen-independent human prostate cancer cell lines.
    [Tumour Biol]
    Abstract

    Knockdown of Ubiquitin Associated Protein 2-Like Inhibits the Growth and Migration of Prostate Cancer Cells
    Investigators found that ubiquitin associated protein 2-like (UBAP2L) was expressed in a number of prostate carcinoma cell lines. They report that UBAP2L may play a role in prostate cancer growth and metastasis, and knockdown of UBAP2L by RNA interference may serve as a potential therapeutic approach for prostate cancer. [Oncol Rep] Abstract

    CLINICAL RESEARCH

    Docetaxel Rechallenge in Patients with Metastatic Castration-Resistant Prostate Cancer
    Investigators evaluated the benefit of docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer relapsing after an initial good response to first-line doxetaxel. [BJU Int] Abstract

    Zoledronic Acid Improves Clinical Outcomes in Patients with Bone Metastatic Hormone-Naïve Prostate Cancer in a Multicenter Clinical Trial
    Scientists assessed whether zoledronic acid added to the effect of combined androgen blockade in patients with hormone-naive bone metastatic prostate cancer. [Anticancer Res] Abstract

    Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.

     
    REVIEWS
    Evolving Therapeutic Concepts in Prostate Cancer Based on Genome-Wide Analyses
    Although androgen deprivation therapy retains an important role in the management of castration resistant prostate cancer, the authors review a broader spectrum of therapeutic targets that may improve patient response and delay development of advanced disease. [Int J Oncol] Abstract

    Visit our reviews page to see a complete list of reviews in the prostate cell research field.

     
    INDUSTRY NEWS
    Prostate Cancer Foundation Announces 2014 Movember-PCF Challenge Awards
    The Prostate Cancer Foundation (PCF) announced that the partnership with the Movember Foundation has resulted in seven new Challenge Awards for 2014. In total, the 2014 Movember-PCF Challenge Awards will be funding 49 investigators hailing from ten cancer centers across the United States. [Prostate Cancer Foundation]
    Press Release

    Glide Pharma Takes Exclusive Worldwide Rights to Novel Diagnostic Technology for Prostate Cancer
    Glide Pharmaceutical Technologies Ltd. announced that it has taken an exclusive worldwide license to an innovative prostate cancer diagnostic technology from FScan Ltd, a Durham University spin-out company.
    [Glide Pharmaceutical Technologies Ltd.]
    Press Release

    From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

     
    POLICY NEWS
    National Institutes of Health (United States)

    Food and Drug Administration (United States)

    Center for Biologics Evaluation and Research (United States)

    European Medicines Agency (European Union)

    Medicines and Healthcare Products Regulatory Agency (United Kingdom)

    Therapeutic Goods Administration (Australia)

     
    EVENTS
    NEW Global Cancer Conference & Medicare Summit 2014
    September 15-17, 2014
    Hyderabad, India

    NEW FAST 2014: Functional Analysis & Screening Technologies Congress
    November 17-19, 2014
    Boston, United States

    Visit our events page to see a complete list of events in the prostate cell community.

     
    JOB OPPORTUNITIES
    NEW Postdoctoral Fellow – Cancer and miR Biology (Thomas Jefferson University Hospital)

    PhD Position – Prostate Cancer Research (Institute of Oncology Research)

    Postdoctoral Position – Cancer Biology/Genomics (Cornell University)

    Postdoctoral Research Fellow – Mechanism of Gene Regulation in Prostate Cancer Development and Bone Metastasis (Brigham & Women’s Hospital – Harvard Medical School)

    Associate Research Scientist – Molecular Mechanisms that Regulate Prostate Tumor Initiation and Formation of Cancer Stem Cells (Columbia University)

    Postdoctoral Fellow – Computational Biology (Netherlands Cancer Institute)

    Postdoctoral Fellow – Prostate Cancer Research (Institute of Oncology Research)

    Postdoctoral Fellow – Translational Prostate Cancer (Cleveland Clinic)

    Scientist – Prostate Cell Research (STEMCELL Technologies Inc.)

    Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

    Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

    Research Associate – Cell Separation (STEMCELL Technologies Inc.)


    Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

     

    Have we missed an important article or publication in Prostate Cell News? Click here to submit!

    Comments or suggestions? Submit your feedback here

    Learn more about Prostate Cell News: Archives | Events | Contact Us